Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 703-705, 2010.
Artigo
em Chinês
| WPRIM
| ID: wpr-293522
ABSTRACT
<p><b>OBJECTIVE</b>To observe the efficacy and side effects of transarterial chemoembolization (TACE) combined with sorafenib for advanced hepatocellular carcinoma (HCC).</p><p><b>METHODS</b>Forty patients with HCC were treated with sorafenib (400 mg bid) after TACE. The efficacy was evaluated according to RECIST 1.1 criteria, and side effects were assessed by NCI CTC 3.0 criteria.</p><p><b>RESULTS</b>Among the forty cases, one case achieved complete remission (CR), seven cases achieved partial remission (PR), nineteen cases achieved stable disease (SD) and thirteen cases had progressive disease (PD). The disease control rate (DCR) was 67.5%. The overall survival time was 1 - 18 months, and 1-year survival rate was 54.0%. The major adverse events were hand-foot skin reaction, diarrhea and thrombocytopenia.</p><p><b>CONCLUSION</b>The combined therapy of TACE and sorafenib is effective and well tolerated for advanced HCC.</p>
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Compostos Organoplatínicos
/
Patologia
/
Compostos de Fenilureia
/
Piridinas
/
Terapêutica
/
Trombocitopenia
/
Benzenossulfonatos
/
Indução de Remissão
/
Doxorrubicina
/
Taxa de Sobrevida
Tipo de estudo:
Estudo observacional
/
Estudo prognóstico
Limite:
Adolescente
/
Adulto
/
Idoso
/
Feminino
/
Humanos
/
Masculino
Idioma:
Chinês
Revista:
Chinese Journal of Oncology
Ano de publicação:
2010
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS